Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption. Recently the osteoclast differentiation factor (ODF), better termed RANKL (receptor activator of NF-B ligand), expressed by osteoblasts has been cloned as well as its cognate signaling receptor, receptor activator of NFB (RANK), and a secreted decoy receptor osteoprotegerin (OPG) that limits RANKL's biological action. We determined that the breast cancer cell lines MDA-MB-231, MCF-7, and T47D as well as primary breast cancers do not express RANKL but express OPG and RANK. MCF-7, MDA-MB-231, and T47D cells did not act as surrogate osteoblasts to support osteoclast formation in coculture experiments, a result consistent with the fact that they do not express RANKL. When MCF-7 cells overexpressing PTH-related protein (PTHrP) were added to cocultures of murine osteoblasts and hematopoietic cells, osteoclast formation resulted without the addition of any osteotropic agents; cocultures with MCF-7 or MCF-7 cells transfected with pcDNAIneo required exogenous agents for osteoclast formation. When MCF-7 cells overexpressing PTHrP were cultured with murine osteoblasts, osteoblastic RANKL messenger RNA (mRNA) levels were enhanced and osteoblastic OPG mRNA levels diminished; MCF-7 parental cells had no effect on RANKL or OPG mRNA levels when cultured with osteoblastic cells. Using a murine model of breast cancer metastasis to bone, we established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma PTHrP concentrations and hypercalcaemia compared with parental or empty vector controls. (Endocrinology 140: [4451][4452][4453][4454][4455][4456][4457][4458] 1999) 
I
T HAS LONG been recognized that breast cancers have the ability to invade and grow as metastases in bone (1) . Some breast cancer cell lines have been shown to induce osteolytic lesions in animal models that mimic the metastatic process in clinical breast cancer (2, 3) , but the factors favoring breast cancer growth in bone remain to be resolved. We and others have established that breast cancer cell lines and primary breast cancers have a number of phenotypic properties in common with bone cells, for example in their expression of calcitonin receptors, bone sialoprotein, cathepsin K, and osteopontin (4, 5) , and we have proposed that these properties may contribute to a breast cancer's capacity to establish and grow in bone (4) . Additionally, the production of boneresorbing factors (such as PTH-related protein, PTHrP) by breast cancer cells may be among the properties that contribute to this (6, 7) , although it is likely that other features also favor growth in skeletal tissue.
Most breast cancer metastases in bone form osteolytic lesions, in contrast with bone secondaries from prostate cancer which are osteosclerotic (1) . Although it has been postulated that bone destruction by breast cancer is mediated directly by tumor cells (1) , most evidence indicate that breast cancerinduced bone destruction is mediated by the osteoclast. Support for the latter include 1) breast cancers express cytokines (such as IL-1, IL-6, LIF, prostaglandin E 2 (PGE 2 ), tumor necrosis factor-␣ (TNF␣) and PTHrP) which can influence osteoclast formation (1); 2) histologic analysis of osteolytic lesions reveal tumor adjacent to osteoclasts resorbing bone; 3) and use of bisphosphonates, potent inhibitors of osteoclastic bone resorption, in women with breast cancer metastases to bone results in reduced skeletal morbidity (8, 9) .
The process of mouse osteoclast formation can be studied in vitro by culturing bone marrow culture cells and by coculture of osteoblastic stromal cells with hematopoietic cells, both of which result in the formation of bona vide osteoclasts in response to various osteotropic factors; the osteoclasts stain for tartrate-resistant acid phosphatase (TRAP), are multinucleated, exhibit calcitonin receptors (CTR) and most importantly can resorb bone (10, 11) . In both systems, stromal osteoblasts support osteoclast formation from precursors of hematopoietic origin.
Recently the stromal cell-derived osteoclast differentiation factor (ODF) or osteoprotegerin ligand (OPGL) has been identified, and a soluble form of the molecule in combination with M-CSF can generate osteoclasts from hematopoietic cells in the absence of osteoblastic stromal cells (11) (12) (13) (14) : it was also identified by its ability to induce NFB and apoptosis of T-cells as receptor activator of NF-B ligand (RANKL) and tumor necrosis factor-related activation-induced cytokine (TRANCE), respectively (15) (16) (17) . For simplicity, will we adopt its nomenclature as RANKL, which represents the functional property that has been described for this molecule. RANKL is a member of the tumor necrosis factor (TNF) family and is a membrane-bound molecule, there is no evidence for an alternatively spliced form of this molecule, although the molecule is shed from the plasma membrane as a result of protease action from HEK293 cells overexpressing RANKL/OPGL (12) . Two receptors for RANKL have been proposed. The first, which aided the identification RANKL was osteoprotegerin (OPG), also reported as osteoclastogenesis inhibitory factor (OCIF) (18, 19) . OPG is a secreted TNF receptor family member and has a relatively wide distribution. Overexpression of OPG in mice resulted in osteopetrosis (18) . Conversely, mice deficient in OPG demonstrate osteoporosis and calcification of the aorta (20) . In agreement with the phenotypes of mice with altered OPG production, recombinant OPG inhibited osteoclast formation in cocultures of mouse osteoblastic cells and hematopoietic cells (12, 13) . The ability of OPG to bind to RANKL and limit the biological actions of RANKL suggested that OPG may function as a decoy receptor (12, 13, 19, 21) . The second, putative receptor, and likely responsible for signaling RANKL biological actions, appears to be receptor activator of NFB (RANK) (15) , although other hitherto unrecognized receptors of the TNF-receptor family may have similar capabilities. In this study, we have investigated the expression of RANKL, OPG, and RANK in breast cancer cell lines and primary tumors. We have also investigated whether breast cancers can directly support or indirectly influence osteoclastogenesis using the murine coculture system and we have demonstrated the ability of breast cancer cells to regulate RANKL expression of stromal osteoblasts. Finally, we have assessed the in vivo osteolytic potential of breast cancer cell lines which differ in their osteoclast-inductive capacity in vitro.
Materials and Methods

Animals, cell lines, and drugs
Male newborn (0 -1 day old) C57/BL6J mice were purchased from Monash University Animal Services Centre (Clayton, Australia). 1␣,25(OH) 2 D 3 was purchased from Wako Pure Chemical Co. (Osaka, Japan), and PGE 2 was obtained from Sigma (St. Louis, MO).
Coculture system
Osteoblastic cells were prepared from the calvaria of newborn mice by sequential digestion with 0.1% collagenase (Worthington Biochemical Corp. Co., Freefold, Australia) and 0.2% dispase (Godo Shusei, Tokyo, Japan). Bone marrow was obtained from the femur and tibia of adult C57BL6J male mice. Osteoblastic cells and/or breast cancer cells were cocultured with spleen or marrow cells as previously described (22, 23) . The expression of calcitonin receptors was also assessed by autoradiography using [
125 I]-salmon calcitonin as described (22) and resultant cells from coculture experiments were tested for their ability to resorb bone (24) .
Tissue specimens
Twelve breast lesions were collected from patients undergoing resective surgery at St. Vincent's Hospital. The tissues were immediately placed on dry ice and stored at Ϫ70 C. The tissues examined were all infiltrating ductal carcinomas with two tumors containing a ductal carcinoma in situ component.
RNA extraction, complementary DNA (cDNA) synthesis, and PCR
Total RNA extraction from the tissues, cDNA synthesis, and PCR were performed as described (25) . Oligonucleotides were designed to amplify and detect human RANKL (GenBank accession number AF019047), murine RANKL (GenBank accession number AF019048), human OPG (GenBank accession number U94332), murine OPG (GenBank accession number U94331) and human RANK (GenBank accession number AF018253) ( Table 1) . Finally, for glyceraldehyde phosphate dehydrogenase (GAPDH) primers used have been published previously GAPDH-1, GAPDH-2, GAPDH-3, and GAPDH-4 (25) . The specificity of the products was confirmed by Southern blot detection using a 32 Plabeled internal oligonucleotide probe, as previously described (25) or by nucleic acid sequencing of amplified products. Bound probe was detected by PhosphorImager analysis (Molecular Dynamics, Inc., Sunnyvale, CA).
Stable transfection of MCF-7 cells
Full-length prepro-PTHrP (1-139) was cloned into the mammalian expression plasmid pcDNAIneo and was subsequently introduced into the MCF-7 cell lines by calcium phosphate precipitation (26) . MCF-7 cells were also transfected with pcDNAIneo vector alone to act as a further control. Single clones were isolated by limiting dilution in the presence of the selective marker G418 (Sigma, St. Louis, MO). Clones were screened by measuring secreted PTHrP in serum-free 24 h conditioned media and by messenger RNA (mRNA) levels. The levels of PTHrP secreted by these cells in conditioned media for 48 h, corrected for 10 
In vivo experiments
Animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio and were in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Female nude mice 4 -6 weeks of age were housed in laminar flow isolated hoods with 12-h light, 12-h dark cycle. Water supplemented with vitamin K and autoclaved mouse chow were provided ad libitum.
Whole blood samples for ionized calcium concentration were obtained by retro-orbital puncture under metofane anesthesia. Blood samples for PTHrP measurement were similarly obtained and collected on ice in vacutainer tubes containing EDTA (Becton Dickinson and Co., NJ) and 400 IU/ml aprotinin (Sigma, St. Louis, MO).
Tumor inoculation into the left cardiac ventricle was performed while the mice were anesthetized with a ketamine/xylazine mixture and positioned ventral side up based on a modification of Arguello (27) . Because MCF-7 cells are estrogen dependent, mice were implanted with a 60-day slow release 17␤-estradiol pellet (0.5 mg, 3 mm; Innovative Research of America, Sarasota, FL) before tumor inoculation. The left cardiac ventricle was punctured percutaneously using a 27-gauge needle attached to a 1-ml syringe containing suspended tumor cells. Visualization of bright red blood entering the hub of the needle in a pulsatile fashion indicated correct position in the left cardiac ventricle.
Bone metastasis
Mice were inoculated with tumor cell suspensions of MCF-7 PTHrP 139c, MCF-7 pcDNAIneo or MCF-7 cells into the left cardiac ventricle (n ϭ 5 per group) on day 0. Baseline radiographs and body weights as well as blood for Ca 2ϩ and plasma PTHrP concentrations were obtained at this time. Radiographs were taken on day 21 and then weekly until they were killed. At the time mice were killed, blood was collected for Ca 2ϩ and PTHrP measurement, and all bones and soft tissues were harvested and fixed in formalin for histologic analysis. Autopsy was performed on all mice, and those with tumor in the chest were excluded from analysis, as this indicated that part or all of the tumor inoculum did not properly enter the left cardiac ventricle. This experiment was performed twice with similar results obtained.
Ca 2ϩ measurement
Ca 2ϩ concentrations were measured in whole blood using a Ciba Corning, Inc. 634 ISE Ca 2ϩ /pH analyzer (Medfield, MA) and adjusted using the internal algorithm of the instrument to pH 7.4. Samples were run in duplicate and the mean value recorded.
PTHrP assay
PTHrP concentrations were measured in conditioned media and in plasma using a two-site immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA), which uses two polyclonal antibodies that are specific for the N-terminal-(1-40) and-(60 -72) portions of PTHrP and has a calculated sensitivity of 0.3 pmol/liter (28) .
PTHrP concentrations in conditioned media samples were calculated from a standard curve generated by adding recombinant PTHrP to the specific type of medium (unconditioned) used and were considered undetectable if media concentrations were Ͻ 0.3 pmol/liter before correction for cell number.
Radiographs and measurement of osteolytic lesion area
Animals were x-rayed in a prone position against the film (22 ϫ 27 cm X-Omat AR, Eastman Kodak Co., Rochester, NY) and exposed with x-rays at 35 KVP for 6 sec using a Cabinet x-ray system-Faxitron Series, Hewlett-Packard Co. (Model 43855A; Faxitron X-Ray Corp., Buffalo Grove, IL). All radiographs were evaluated in blinded fashion. The area of osteolytic bone metastases was calculated using a computerized image analysis system. Video images of radiographs were captured using a frame grabber board (Targa ϩ , Truevision, Inc.) on a PC system. Quantitation of lesion area was performed using image analysis software (Java, Jandal Video analysis, Jandel Scientific, CA).
Bone histology and histomorphometry
Fore-and hindlimb bones were removed from mice at time of killing, fixed in 10% buffered formalin, decalcified in 14% EDTA, and embedded in paraffin wax. Sections were cut using a standard microtome, placed on poly-l-lysine-coated glass slides and stained with hematoxylin, eosin, orange G and phloxine.
The following variables were measured in midsections of tibiae and femora, without knowledge of treatment groups, to assess tumor involvement: total tumor area and osteoclast number per millimeter of tumor/bone interface. Histomorphometic analysis was performed on an OsteoMeasure System (Osteometrics, Atlanta,GA).
Statistical analysis
Results are expressed as the mean Ϯ the sem. Data were analyzed by repeated measures ANOVA followed by Turkey-Kramer post test. P values of Ͻ 0.05 were considered significant.
Results
Ability to support osteoclast formation
Because breast cancers have the ability to induce osteolytic lesions, we determined whether breast cancer cell lines could substitute as an osteoblastic stromal cell to support osteoclast formation. When mouse primary calvarial osteoblasts were cocultured with marrow cells, in the presence of 1␣,25(OH) 2 D 3 and PGE 2 , for 7 days osteoclasts were formed (TRAP ϩ , MNC, exhibiting CTR and capable of resorbing bone) (Fig.  1A) . In contrast, none of the breast cancer lines MDA-MB-231, T47D, MCF-7, and MCF-7 PTHrP 139c were able to support osteoclast formation when cocultured with hematopoietic cells from neonatal mouse spleen or adult mouse (Fig. 1A) . This indicated that breast cancer cell lines alone were unable to substitute for stromal osteoblasts. No multinucleated osteoclasts were formed when marrow or spleen cells were incubated alone even in the presence of 1␣,25(OH) 2 D 3 and PGE 2 as has been previously described (29) .
We next addressed whether the presence of breast cancer cells could modify the osteoclast-inductive potential of stromal osteoblastic cells when cocultured with hematopoietic cells from adult mouse marrow (Fig. 1B) or neonatal mouse spleen (data not shown). These models are more akin to the in vivo situation, whereby breast cancer cells interact with both osteoblasts and hematopoietic cells. When osteoblastic cells were cultured with hematopoietic cells, osteoclasts were formed in response to treatment with 1␣,25(OH) 2 D 3 and PGE 2 . Similarly, when any of the breast cancer cell lines, MCF-7 (Fig. 1B) , MDA-MB-231 or T47D (not shown), were added in equal numbers to the osteoblastic cells (5 ϫ 10 4 cells/48-well culture plate), osteoclast formation occurred and the resultant osteoclast numbers were similar to that seen with osteoblast and hematopoietic cell cocultures (Fig.  1B) . The small discrepency in osteoclast numbers seen between the osteoblastic coculture and the MCF-7 coculture maybe due to the high level of expression of OPG seen in the MCF-7 cells ( Fig. 2A) , which could diminish osteoclast formation.
Expression of PTHrP by breast cancer cells is known to enhance osteolytic potential of MDA-MB-231 breast cancer cells in vivo (2, 30) . The effect of a PTHrP-overexpressing cell line (MCF-7 PTHrP 139c) on modulating osteoclast formation in coculture was therefore assessed. In cocultures of osteoblasts and hematopoietic cells in which MCF-7 PTHrP 139c cells (5 ϫ 10 4 cells/48-well culture plate, numbers equal to osteoblastic cells) were added to the coculture, TRAP ϩ multinucleated cell formation occurred even in the absence of exogenous osteotropic agents (Fig. 1B) . These cells displayed the properties of osteoclasts i.e. TRAP ϩ , multinucleated, expressed CTR and could resorb bone. Upon addition of 1␣,25(OH) 2 D 3 and PGE 2 osteoclast formation was equivalent to that generated by osteoblasts with these treatments (Fig. 1B) . The resultant osteoclast formation seen with the PTHrP-overexpressing cells in the absence of any osteotropic agents contrasts markedly to that of the parental MCF-7 cell line.
Because the TNF-related ligand (RANKL) and the receptors (OPG, RANK) have been invoked as pivotal molecules in osteoclast formation (21), we determined the expression of RANKL, OPG, and RANK mRNA in breast cancer cell lines and in primary breast cancers. Total RNA was isolated and reverse transcribed then subjected to PCR for 40 cycles of amplification, which represent saturating, nonquantitative, conditions. As controls, RT-PCR was performed on RNA isolated from a giant cell tumor of bone (GCT), which we have determined to express RANKL, OPG, and RANK. As a negative control, PCRs were performed on RNA, which had not been reversed transcribed and no products were detected under these conditions. Consistent with the inability of breast cancer cell lines to support osteoclast formation, the lines MDA-MB-231, T47D, MCF-7, and MCF-7 PTHrP 139c did not express RANKL mRNA, whereas the GCT expressed a single product with nucleotide sequence identity to RANKL (Fig. 2A) . Additionally, none of the primary breast cancers expressed RANKL mRNA ( Fig. 2A) . Because RNA from the primary tumors would represent RNA from both cancer cells and from the normal stroma, this implies that both the stroma and breast cancer cells fail to express RANKL. In contrast, the three breast cancer cell lines and all tumors expressed mRNA for OPG and RANK (Fig. 2A) ; albeit that OPG levels were lower in the T47D cells relative to the MCF-7 and MDA-MB-231 cells as has been reported previously (31) . The MCF-7 PTHrP 139c cells showed an equivalent level of OPG mRNA expression to the parental MCF-7 cells (data not shown). Using the GAPDH primers, a product of the predicted size was amplified from each of the tumor and cell line samples, and amplification of GAPDH mRNA was performed with primers GAPDH-3 and GAPDH-4, as described in the Materials and Methods. PCR products were resolved on a 1% (wt/vol) agarose gel, transferred to a nylon membrane and hybridized with an internal oligonucleotide; RANKL-6 (RANKL), OPG-6 (OPG), RANK-15 (RANK) or GAPDH-1 (GAPDH). Lanes correspond to: negative control; giant cell tumor, GCT; MDA-MB-231, MCF-7, T47D breast cancer cell lines and primary breast tumor samples 1-12. This figure is representative of three independent RT-PCRs. B, RT-PCR analysis of RANKL, OPG and GAPDH mRNA in a coculture system of MCF-7 breast cancer cells and murine osteoblastic cells. PCR amplification of RANKL mRNA was performed with oligonucleotide primer pairs RANKL-1 and RANKL-2 specific to murine RANKL mRNA: amplification of murine OPG mRNA was performed with primers OPG-1 and OPG-2; and amplification of murine GAPDH mRNA was performed with primers GAPDH-2 and GAPDH-4, as described. PCR products were resolved on a 1% (wt/vol) agarose gel, transferred to a nylon membrane and hybridized with an internal oligonucleotide; RANKL-11 (RANKL), OPG-3 (OPG) or GAPDH-1 (GAPDH). Lanes correspond to: MCF-7 cells alone, murine primary osteoblastic cells (POB) alone and coculture of murine primary osteoblasts into MCF-7 parental (P) and MCF-7 PTHrP 139c (O) cells for the times indicated. RNA from the 4-h time point which had not been reversed transcribed acted as the control (-ve). This figure is representative of three independent RT-PCRs.
which hybridized with the internal GAPDH oligonucleotide, GAPDH-1 ( Fig. 2A) , thus confirming the integrity of RNA used.
RANKL mRNA is regulated by osteotropic factors in osteoblasts (13, 32) and its expression relative to that of OPG expression appears to dictate the osteoclast-inductive nature of cells (32) . Thus, we examined the effect of local and systemic factors such as IL-11, PTHrP, transforming growth factor ␤ (TGF␤) and 1␣,25(OH) 2 D 3 to stimulate the expression of RANKL in the MDA-MB-231, T47D, and MCF-7 cell lines. However, none of these agents permitted the expression of RANKL in any of these cell lines (data not shown), suggesting that the RANKL gene in breast cancers is maintained in a transcriptionally inactive state. Such a result is in accordance with the inability of breast cancer cell lines to act in a manner equivalent to osteoblastic stromal cells for differentiation and induction of osteoclasts from hematopoietic cells.
PTHrP expressed by breast cancers modulates osteoblast RANKL production
We have previously established that osteoblastic RANKL mRNA levels can be enhanced by PTH/PTHrP (32). To determine if PTHrP produced by breast cancer cells invoked changes in RANKL mRNA similar to those we observed in response to treatment of primary osteoblasts, murine RANKL and OPG mRNA levels were assessed in cocultures of human breast cell lines and primary murine osteoblasts (Fig. 2B) . MCF-7 parental and the PTHrP overexpressing cell line, MCF-7 PTHrP 139c, were cultured with primary mouse osteoblasts (osteoblasts at 1 ϫ 10 6 cells and MCF-7 at 5 ϫ 10 5 cells per 10 mm Petri dish), and murine RANKL and OPG levels were determined during 7 days of coculture. Mouse RANKL mRNA was induced 2.4 Ϯ 0.2-fold following 8 h of coculture with MCF-7 PTHrP 139c cells and remained elevated for up to 72 h. Levels of murine RANKL mRNA were unaltered in cocultures comprising MCF-7 cells for up to 3 days, then in both MCF-7 and MCF-7 PTHrP 139 cocultures murine RANKL mRNA levels decreased by day 7 (Fig. 2B) . Furthermore, murine OPG mRNA expressed by osteoblastic cells was reduced 6.1 Ϯ 0.5-fold at 8 h when MCF-7 cells overexpressing PTHrP were cocultured with murine osteoblasts compared with parental MCF-7 cells.
In vivo experiments
Given that the MCF-7 cells overexpressing PTHrP enhanced osteoclast formation in murine in vitro cocultures, we sought to establish the role of PTHrP overexpression by the MCF-7 cell line in vivo by intracardiac injection in the nude mouse model. Such a model has demonstrated that MDA- MB-231 cells avidly metastasize to bone and induce osteolysis (30) .
Mice inoculated with the MCF-7 PTHrP 139c developed large bone metastases with osteolysis being evident earlier and to a greater extent than that seen with mice harbouring either the parental cells or cells stably transfected with the vector control only (Fig. 3) . When quantitated by computerized image analysis of radiographs, the differences in lesion area and number were statistically significant (Fig. 3) . The in vitro growth rates of these MCF-7 cells showed no significant difference between the MCF-7 PTHrP-139 and the empty vector or parental cells (data not shown) therefore the difference in tumor size is not attributable to the growth rate of the various MCF-7 cells. Histomorphometric analysis of bone (Fig. 4, A and B) indicate that osteoclast number per mm of tumor-bone interface was markedly greater, as was tumor area, in mice bearing MCF-7 PTHrP-139 tumors compared with the control parental and empty vector groups. Significant hypercalcemia was evident in mice bearing the MCF-7 PTHrP-139 cells, whereas mice bearing the MCF-7 pcDNAIneo (empty vector) or parental cells, remained normocalcemic (Fig. 4C) . Concomitant with this hypercalcemia, plasma PTHrP concentrations were significantly greater at the time mice were killed (Fig. 4D) in the MCF-7 PTHrP-139c bearing mice. There was no significant difference in body weight between mice bearing tumors of MCF-7 PTHrP 139c, empty vector or parental cells (not shown).
Discussion
It is well established that breast cancers have the capability to establish and grow as metastases in bone, however the mechanism underlying their ability to induce osteolysis remains unresolved. Although some authors have suggested that breast cancer cells alone have the capacity to degrade the bone matrix, lesions of bone or dentine slices attributable to breast cancer cells observed in vitro are not of the magnitude of those resulting from osteoclast-mediated bone destruction (1). Our present series of experiments provide unequivocal evidence that several breast cancer cells were unable to act as surrogate osteoblasts to support osteoclast formation in vitro. Moreover, breast cancer cell lines such as T47D, MCF-7, and MDA-MB-231 do not express the TNF-related ligand, RANKL, which is required along with M-CSF for the differentiation of hematopoietic cells into osteoclasts. Further RANKL mRNA expression could not be induced in response to treatment with any osteotropic agents known to enhance osteoclast formation, and no expression was detected in a series of surgically obtained primary breast cancers.
Several studies have implicated PTHrP as a crucial factor in the process of breast cancer metastases in bone (2, 30) . This study extends these observations to demonstrate that PTHrP produced by breast cancer cells is sufficient to stimulate osteoclast formation in marrow cultures with osteoblastic cells without the requirement for exogenous osteotropic agents such as 1,25␣ (OH) 2 D 3 , PGE 2 , or IL-11. In such cocultures we show the capacity of breast cancer cell-derived PTHrP to induce osteoblastic RANKL mRNA levels and reduce osteoblastic OPG mRNA levels, the net effect of which is anticipated to enhance osteoclast formation. Such a finding is concordant with the osteoclast induction seen when breast cancer cells overexpressing PTHrP were added to cocultures and to previous in vitro experiments where exogenous PTH/ PTHrP similarly modulate RANKL and OPG mRNA levels (32) .
Finally, and most significantly, we extend these in vitro findings to an in vivo model of metastasis using the well established nude mouse model whereby cancer cells were administered via intracardiac injection. Whilst parental MCF-7 cells had a low prevalence for metastasis in bone, when PTHrP was overexpressed the cells avidly metastasized to bone and induced osteolysis with accompanying hypercalcemia. The MCF-7 cells have not been shown previously to be capable of metastatic growth in the nude mouse.
Combining the in vitro and in vivo data, a possible model for the severe osteolysis induced by breast cancers is proposed in Fig. 5 . This model extrapolates from our previous findings (2) and results presented herein. As a consequence of breast cancer cells establishing in the bone microenviron- ment, PTHrP secreted from these cells can act in a paracrine/ juxtacrine manner on osteoblastic cells, increasing RANKL expression and limiting OPG expression. This favors the formation and the survival of osteoclasts because RANKL has also been demonstrated to limit osteoclast apoptosis (14) . Enhancement of osteoclast numbers and their activity results in pronounced osteolysis with the subsequent release of bone-derived growth factors such as TGF␤. TGF␤ is a potent stimulator of PTHrP production acting both transcriptionally and posttranscriptionally via mRNA stabilization (33, 34) . Recently, TGF␤ has been demonstrated to decrease RANKL mRNA and enhance OPG mRNA levels in osteoblasts (35) . Such a mechanism may well account for the local control of bone formation and resorption. However, when breast cancer cells have established in the bone environment, differential roles of bone-derived growth factors, including TGF␤, can emerge. Thus for example, they could modify the production of cytokines and growth factors by breast cancer cells and osteoblastic cells in ways that could influence RANKL, OPG and the signaling receptor RANK.
This work provides conclusive evidence that breast cancers are incapable of stimulating osteoclast formation as a result of a direct interaction with hematopoietic cells, but facilitate their lytic potential via the osteoblast. The demonstration that breast cancer cell-derived PTHrP can modulate osteolysis, coupled with the knowledge that OPG can limit osteoclast formation, provides two unique secreted targets to address for therapy to limit osteolysis as a result of breast cancer metastasis in bone. FIG. 5 . Potential effects of PTHrP on osteoclast formation. Breast cancer cells express OPG, RANK and PTHrP. Secreted PTHrP leads to an enhancement of osteoblastic RANKL mRNA and reduction in osteoblastic OPG mRNA. RANKL engages its cognate receptor RANK on cells at the macrophage/monocyte lineage permitting differentiation of these cells into functional osteoclasts. Finally, as a result of bone resorption, TGF␤, a potent enhancer of PTHrP production, is released from the bone matrix: TGF␤ may also act on the osteoblast to enhance PTHrP production from osteoblast. Such a cycle would potentiate the osteolytic potential of tumors once established in bone.
